Core Laboratories Inc. /DE/ (CLB) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-04

Key Insights

Mark Tattoli, SVP General Counsel & Secretary, sold 97 shares at $14.07 per share on 05/01/2026, representing a modest insider sale with no significant volume implications.
Tattoli received 250 restricted shares as compensation on 05/01/2026, vesting annually over six years contingent on continued employment, indicating standard executive equity incentive practices.
Total beneficial ownership of 27,610.621 common shares (direct) plus 1,694.842 indirect shares in a 401(k) plan demonstrates moderate insider stake of approximately 29,305 shares overall.
The transaction was executed under a Rule 10b5-1 trading plan, suggesting pre-planned, routine stock activity rather than opportunistic trading based on material non-public information.

Want the newest filings?

This analysis covers the filing from 2026-05-04. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-08

The reporting person, Katherine Murray, acquired 8,069 shares of common stock through the vesting of restricted shares on April 1, 2026.
The reporting person was granted an additional 7,895 restricted shares on April 1, 2026, which will vest after a one-year period, subject to continued service on the board.
The reporting person's direct beneficial ownership of the company's common stock increased from 21,221 shares to 29,290 shares as a result of the transactions.

Filed: 2026-04-07

Curt Anastasio, a director of Core Laboratories Inc. /DE/ (CLB), acquired 8,069 shares of common stock through the vesting of restricted shares.
Anastasio also received an additional 7,895 restricted shares that will vest in one year, subject to a deferral election.
This insider transaction suggests Anastasio maintains confidence in the company's future performance and aligns his interests with shareholders.

Filed: 2026-04-07

The reporting person, Harvey Robert Klingensmith, acquired 8,069 shares of common stock through the vesting of restricted shares on April 1, 2026. This indicates insider ownership and potential confidence in the company's future performance.
An additional 7,895 restricted shares were granted to the reporting person, which will vest on April 1, 2027, subject to the terms of issuance. This suggests ongoing equity-based compensation and long-term incentives for the director.
The reporting person holds a direct ownership of 50,031 shares of common stock following the reported transactions, indicating a substantial stake in the company.

Filed: 2026-04-07

The reporting person, Kwaku Temeng, acquired 8,069 shares of common stock through the vesting of restricted shares on April 1, 2026, indicating insider ownership and confidence in the company.
The reporting person was granted an additional 7,895 restricted shares that will vest on April 1, 2027, further aligning their interests with long-term shareholders.
The reporting person's direct ownership of 33,597 shares suggests a significant personal stake in the company's performance and potential for future growth.

Filed: 2026-04-07

The reporting person, Robert F. Martinovich, acquired 8,069 shares of Core Laboratories Inc. common stock through the vesting of restricted shares on April 1, 2026.
Martinovich was also granted an additional 7,895 restricted shares on April 1, 2026, which will vest one year later on April 1, 2027.
The insider transactions indicate Martinovich's continued commitment to and confidence in the company's long-term prospects.

Filed: 2026-04-07

The reporting person, Martha Z. Carnes, acquired 8,069 shares of Core Laboratories Inc. common stock through the vesting of restricted shares, increasing her direct beneficial ownership to 54,397 shares.
Carnes also received an additional 7,895 restricted shares that will vest in one year, on April 1, 2027, subject to continued service on the company's board.
The insider transaction appears to be part of Carnes' ongoing compensation as a director of Core Laboratories, with the vesting of previously awarded equity grants.

Filed: 2026-02-17

Insider Mark Damian Tattoli, SVP, General Counsel and Secretary, has acquired 33,490 performance shares in Core Laboratories Inc. that will vest based on the company's Return on Invested Capital (ROIC) performance over the next three years.
The vesting of the performance shares is tied to achieving specific ROIC percentile thresholds relative to the Bloomberg Peer Group, with the maximum 175% vesting if Core Laboratories reaches the 85th percentile or higher.
The award is subject to a reduction in the number of shares that can vest above 100% if the company's total shareholder return for the performance period is negative.

Filed: 2026-02-17

Gwendolyn Gresham, SVP at Core Laboratories Inc. /DE/ (CLB), acquired 33,490 performance shares on 02/12/2026, indicating potential executive confidence in the company's future performance.
The performance shares will vest based on Core Laboratories' Return on Invested Capital (ROIC) performance relative to its Bloomberg Peer Group, incentivizing the executive to drive strong financial results.
The award's vesting is subject to a three-year performance period and potential reduction if the company's total shareholder return is negative, aligning executive compensation with shareholder interests.

Filed: 2026-02-17

Insider Christopher Scott Hill, SVP & CFO, acquired 70,008 performance shares that will vest based on the company's ROIC performance over a 3-year period.
The performance shares include a 50% vesting threshold at the 35th percentile of ROIC, 100% vesting at the 55th percentile, and up to 175% vesting at the 85th percentile.
Vesting of the performance shares above 100% will be reduced by 50% if the company's absolute total shareholder return for the period is negative.

Filed: 2026-02-17

The reporting person, Lawrence Bruno, who is the Chairman and CEO of Core Laboratories Inc. /DE/ (CLB), acquired 204,340 performance shares on 02/12/2026. The vesting of these shares is tied to the company's performance on Return on Invested Capital (ROIC) relative to its Bloomberg Peer Group over a 3-year period.
The performance shares vest on a graduated scale, with 50% vesting if the company is in the top 35th percentile of ROIC, 100% vesting if in the top 55th percentile, and 175% vesting if at or above the 85th percentile. The vesting is also subject to a clawback if absolute total shareholder return is negative.
This significant insider acquisition of performance-based shares suggests the CEO's confidence in the company's future performance and aligns his interests with those of shareholders.

Filed: 2026-02-17

The reporting person, Tao Sow Hang, is the Chief Accounting Officer and Treasurer of Core Laboratories Inc. /DE/ (CLB), indicating their senior leadership position within the company.
Tao Sow Hang acquired 7,526 performance shares on February 12, 2026, which will vest on December 31, 2028 based on the company's return on invested capital (ROIC) performance relative to its Bloomberg Peer Group.
The performance share award incentivizes the reporting person to drive the company's ROIC performance, aligning their interests with those of the shareholders.

Filed: 2026-01-05

The Chairman and CEO of Core Laboratories Inc. /DE/ (CLB) exercised 180,722 performance shares that vested on December 31, 2025, indicating the company met its return on invested capital performance targets.
The reporting person also sold 112,681 shares of common stock on December 31, 2025, likely to cover tax obligations related to the vesting of the performance shares.
The net change in the reporting person's beneficial ownership position suggests an alignment between executive compensation and company performance.

Filed: 2026-01-05

Insider Mark Tattoli, Senior Vice President, General Counsel and Secretary, exercised 24,952 performance shares and sold 14,310 shares on 12/31/2025 for $16.03 per share.
Tattoli now holds 41,670.621 shares directly and 1,714.842 shares indirectly, indicating continued ownership alignment with the company's performance.
The company's performance criteria for the performance share award were met at 116.5% of the target level, suggesting strong operational and financial execution.

Other reports for Core Laboratories Inc. /DE/

Quarterly Report Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.